{"id":"anti-il5-receptor-antibodies","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Upper respiratory tract infections"},{"rate":null,"effect":"Arthralgia"}]},"_chembl":{"chemblId":"CHEMBL575966","moleculeType":"Small molecule","molecularWeight":"361.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These monoclonal antibodies bind to the IL-5 receptor (IL-5R) on the surface of eosinophils and their precursors, blocking the signaling pathway that promotes eosinophil survival, activation, and recruitment. By inhibiting IL-5 signaling, these antibodies reduce circulating and tissue eosinophil counts, thereby suppressing eosinophil-mediated inflammatory responses in conditions characterized by eosinophilic inflammation.","oneSentence":"Anti-IL-5 receptor antibodies block the interleukin-5 receptor on eosinophils, preventing eosinophil activation and reducing eosinophilic inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:17:07.806Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Eosinophilic asthma"},{"name":"Chronic rhinosinusitis with nasal polyps"},{"name":"Eosinophilic granulomatosis with polyangiitis (EGPA)"}]},"trialDetails":[{"nctId":"NCT04108962","phase":"PHASE4","title":"Benralizumab in the Treatment of Patients With Severe Asthma With ABPA","status":"WITHDRAWN","sponsor":"Baylor Research Institute","startDate":"2019-12-23","conditions":"ABPA, Severe Asthma, Allergic Bronchopulmonary Aspergillosis","enrollment":""},{"nctId":"NCT05001529","phase":"PHASE4","title":"Flow Cytometry Analysis of Eosinophils in Severe Asthma Patients.","status":"UNKNOWN","sponsor":"Scarlata, Simone, M.D.","startDate":"2021-03-18","conditions":"Severe Asthma","enrollment":80},{"nctId":"NCT00768079","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563).","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2009-02-02","conditions":"Asthma","enrollment":110},{"nctId":"NCT04181190","phase":"","title":"Effects of Anti-IL5 Biological Treatments on Blood IgE Levels in Severe Asthmatic Patients","status":"COMPLETED","sponsor":"Università degli Studi di Ferrara","startDate":"2019-10-11","conditions":"Asthma, Asthma; Eosinophilic","enrollment":130},{"nctId":"NCT00783289","phase":"PHASE2","title":"A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2008-11-14","conditions":"Asthma","enrollment":35},{"nctId":"NCT00659659","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With Asthma","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2008-01","conditions":"Asthma","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"anti IL5 receptor antibodies","genericName":"anti IL5 receptor antibodies","companyName":"Scarlata, Simone, M.D.","companyId":"scarlata-simone-m-d","modality":"Biologic","firstApprovalDate":"","aiSummary":"Anti-IL-5 receptor antibodies block the interleukin-5 receptor on eosinophils, preventing eosinophil activation and reducing eosinophilic inflammation. Used for Eosinophilic asthma, Chronic rhinosinusitis with nasal polyps, Eosinophilic granulomatosis with polyangiitis (EGPA).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}